In vivo incorporation of bromodeoxyuridine into proliferating cells in the marrow and its effects on granulocyte-macrophage progenitor cells.
Bromodeoxyuridine (BUdR), a potential radiosensitizing drug, was given by intravenous infusion at 650-1000 mg/m2/day for up to 12 days. In vivo incorporation into human bone marrow was assayed by differential chromatid staining as well as by comparison of in vitro radiation survival curves of granulocyte-macrophage progenitor cells scored at both day 7 and day 14. Although a difference was found in the radiation survival of control (untreated) day-7 progenitor cells (Do = 1.39 Gy) and day-14 progenitor cells (Do = 0.89 Gy), a similar degree of in vitro radiosensitization was found for BUdR-treated bone marrow progenitor cells scored at day 7 and day 14. The culture technique provided a bioassay for the in vivo action of BUdR. BUdR treatment produced transient moderate myelosuppression that probably resulted from BUdR incorporation into normal marrow cells.
D001853:Bone Marrow / Q000528:radiation effects; D001854:Bone Marrow Cells; D001973:Bromodeoxyuridine / Q000378:metabolism / Q000494:pharmacology*; D002469:Cell Separation; D002877:Chromosomes, Human / Q000378:metabolism; D005434:Flow Cytometry; D006098:Granulocytes / Q000166:cytology*; D006801:Humans; D008264:Macrophages / Q000166:cytology*; D013234:Stem Cells / Q000187:drug effects*
D001973:Bromodeoxyuridine